Sign up to save your podcasts
Or
Share ICIs In Esophageal & GEJ Cancers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ICIs In Esophageal & GEJ Cancers
Updates on the use of immune-checkpoint inhibitors in esophageal and gastro-esophageal junction (GEJ) cancers.
First, adjuvant nivolumab (Checkmate 577). Then, pembrolizumab + chemo for initial treatment of metastatic disease (Keynote 590). Also, we mention 2 new approvals for myeloma: the 1st CAR-T for the disease and an expanded indication for isatuximab.
View all episodes
By John Bossaer
4.9
181181 ratings
Updates on the use of immune-checkpoint inhibitors in esophageal and gastro-esophageal junction (GEJ) cancers.
First, adjuvant nivolumab (Checkmate 577). Then, pembrolizumab + chemo for initial treatment of metastatic disease (Keynote 590). Also, we mention 2 new approvals for myeloma: the 1st CAR-T for the disease and an expanded indication for isatuximab.
More shows like OncoPharm
View all
JAMA Clinical Reviews
495 Listeners
ASCO Daily News
57 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
The ONS Podcast
197 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
715 Listeners
OncLive® On Air
22 Listeners
Oncology Today with Dr Neil Love
57 Listeners
The Curious Clinicians
369 Listeners
Ninja Nerd
318 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
WolverHeme Happy Hour
30 Listeners